Previous 10 | Next 10 |
ToughBuilt Industries (TBLT) +87%. Zendesk (ZEN) +52% after report near takeout from PE consortium. Moving iMage Technologies (MITQ) +39% authorizes $1 Million Share Repurchase Program. Eton Pharmaceuticals (ETON) +16% hospital products to Dr. Reddy’s for up to...
Seres Therapeutics (MCRB) +11% announces confirmatory results from investigational microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection. Kohl's KSS +10% after entering exclusive talks for $60/share sale to Franchise Group. GitLab GTLB...
Acer Therapeutics (ACER) -17%. Energy Focus (EFOI) -9% after secures $3.5M capital in private placement. Gevo (GEVO) -8% on pricing $150M securities offering. Context Therapeutics (CNTX) -7%. Bright Green (BGXX) -6%. Red Robin Gourmet Burgers (RRGB) -5% on report...
Context Therapeutics press release (NASDAQ:CNTX): Q1 GAAP EPS of -$0.22. Cash, cash equivalents, and restricted cash were $45.7 million at March 31, 2022, compared to $49.7 million at December 31, 2021. Shares +7.7%. For further details see: Context Therapeutics GAAP EPS of -$0.22
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispec...
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022...
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization, binding properties, and T-cell dependent cytotoxicity C...
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today annou...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re looking for the biggest pre-market stock movers for Monday, then we’ve got you covered with a list of gainers and losers for today. Source: Eric Urquhart/Shutterstock.com An earnings report, ...
Context Therapeutics press release (NASDAQ:CNTX): FY Net loss of $10.5M. Cash, cash equivalents, and restricted cash were $49.7 million at December 31, 2021, compared to $0.3 million at December 31, 2020. Context expects that its cash and cash equivalents will be sufficient to fund its operat...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the ...
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...